# Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Source: https://onco.cc/trials/nct06082102/  
OnCo record `nct06082102` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Orelabrutinib, Rituximab and Lenalidomide in non-Hodgkin lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.

## Summary

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma is a phase 3 interventional study registered as NCT06082102 by Beijing InnoCare Pharma Tech Co., Ltd., with 324 participants planned, started 2023-12-19 and due to reach its primary completion in 2028-08-31. Interventions recorded: Orelabrutinib, Rituximab and Lenalidomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06082102
- Phase: 3
- Setting: A Randomized, Controlled, Open-label, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Orelabrutinib Plus Rituximab Versus Lenalidomide Plus Rituximab in Relapsed/Refractory Marginal Zone Lymphoma
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 324

## Sources

- ClinicalTrials.gov NCT06082102: https://clinicaltrials.gov/study/NCT06082102

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Orelabrutinib](https://onco.cc/drugs/orelabrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct06082102.json